All In Biotech

Drug Trial Radar · NCT04753606

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin Therapy

Last checked: Nov 19, 2026Latest source record: Jul 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Feb 18, 2021

Primary completion

May 24, 2021

Study completion Aug 30, 2021

Sponsor

Lead sponsor
NewAmsterdam PharmaIndustry
Sponsor type
Industry
First posted
Feb 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.

Conditions

  • Dyslipidemias
  • High Cholesterol
  • Hypercholesterolemia

Interventions

  • ObicetrapibDrug

    tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]Time frame: 8-weeks
  2. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]Time frame: 8-Weeks
  3. LS Mean Percent Change Iin Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]Time frame: 8-Weeks
  4. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]Time frame: 8-Weeks
  5. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]Time frame: 8-Weeks
  6. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]Time frame: 8-Weeks

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Pinnacle Research Group

    Anniston, Alabama

  • National Research Institute - Huntington Park

    Huntington Park, California

  • National Research Institute - Wilshire

    Los Angeles, California

  • Clinical Trials Research

    Sacramento, California

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Ocala Cardiovascular Research

    Ocala, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • IACT Health

    Columbus, Georgia

  • Evanston Premier Healthcare Research LLC

    Evanston, Illinois

  • Midwest Institute for Clinical Research

    Indianapolis, Indiana

  • Oakland Medical Research Center

    Troy, Michigan

  • Diabetes and Endocrinology Consultants, P.C.

    Morehead City, North Carolina

  • Lillestol Research, LLC

    Fargo, North Dakota

  • Metabolic and Atherosclerosis Research Center

    Cincinnati, Ohio

  • Summit Research Group, LLC

    Munroe Falls, Ohio

  • Monument Health Clinical Research

    Rapid City, South Dakota

  • Health Concepts

    Rapid City, South Dakota

  • Juno Research, LL

    Houston, Texas

  • Manassas Clinical Research Center

    Manassas, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.